Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study

Area of Science:

• Oncology
• Radiology
• Medical Imaging

Background:

• Diffuse large B-cell lymphoma (DLBCL) requires accurate staging and treatment response assessment.
• Positron emission tomography/computed tomography (PET/CT) is a standard imaging modality for DLBCL.
• Diffusion-weighted MRI (DW-MRI) offers potential as an alternative or complementary imaging technique.

Purpose of the Study:

• To compare the efficacy of DW-MRI versus PET/CT in staging DLBCL patients.
• To evaluate the utility of DW-MRI and PET/CT in assessing early treatment response in DLBCL.
• To determine the concordance between DW-MRI and PET/CT in identifying lymphomatous involvement and stage.

Main Methods:

• 12 DLBCL patients underwent pretreatment staging with both DW-MRI and PET/CT.
• 8 patients were rescanned after two chemotherapy cycles for interim response assessment.
• Lesion detection, Ann Arbor staging, apparent diffusion coefficient (ADC), SUVmax, and tumor size changes were analyzed.

Main Results:

• DW-MRI and PET/CT demonstrated 97% agreement in overall lesion detection and 100% agreement in Ann Arbor staging.
• Interim assessment showed significant changes in ADC (85% increase), tumor size (74% decrease), and SUVmax (83% decrease) (p < 0.01).
• DW-MRI provided comparable findings to PET/CT for both staging and early treatment response evaluation.

Conclusions:

• DW-MRI is a valuable tool for staging DLBCL, showing high concordance with PET/CT.
• DW-MRI effectively assesses early treatment response in DLBCL patients, mirroring PET/CT findings.
• DW-MRI offers a comparable alternative to PET/CT for comprehensive evaluation in DLBCL management.